PetSmart and Covidien Shares Spark Interest Among Investors Before Earnings

PetSmart, Inc. (NASDAQ:PETM) will unveil its latest earnings on Wednesday, November 16, 2011. The average estimate of analysts is for net income of 48 cents per share, a rise of 26.3% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 45 cents. Between one and three months ago, the average estimate moved down. It has risen from 44 cents during the last month. For the year, analysts are projecting profit of $2.53 per share, a rise of 25.9% from last year.

Last quarter, the company reported net income of 54 cents per share versus a mean estimate of profit of. The company has beaten estimates for the past three quarters. Analysts are projecting a rise of 7.2% in revenue from the year-earlier quarter to $1.49 billion.

Competitors to Watch: PetMed Express (NASDAQ:PETS), Rite Aid (NYSE:RAD), Walgreen (NYSE:WAG), CVS (NYSE:CVS), Target (NYSE:TGT), Wal-Mart (NYSE:WMT), Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA).

Covidien Ltd. (COV) will unveil its latest earnings on Tuesday, November 15, 2011. The average estimate of analysts is for profit of $1.05 per share, a rise of 25% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from $1.04. Between one and three months ago, the average estimate moved up. It has been unchanged at $1.05 during the last month. For the year, analysts are projecting net income of $3.94 per share, a rise of 16.6% from last year.

The company has beaten estimates the last four quarters and is coming off a quarter where it topped forecasts by 6 cents, reporting profit of $1.01 per share against a mean estimate of net income of 95 cents per share. On average, analysts predict $3.03 billion in revenue this quarter, a rise of 13.5% from the year ago quarter. Analysts are forecasting total revenue of $11.52 billion for the year, a rise of 10.5% from last year’s revenue of $10.43 billion.

Competitors to Watch: C.R. Bard, Inc. (NYSE:BCR), Teleflex Incorporated (NYSE:TFX), Becton, Dickinson and Co. (NYSE:BDX), Baxter International Inc. (NYSE:BAX), Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI), CareFusion Corporation (NYSE:CFN), CONMED Corporation (NASDAQ:CNMD), AngioDynamics, Inc. (NASDAQ:ANGO), and Masimo Corporation (NASDAQ:MASI).

More from The Cheat Sheet